<DOC>
	<DOC>NCT02121522</DOC>
	<brief_summary>The present trial will use an open label design to investigate the effect of BI 144807 on central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD patients. A further objective is to collect data on adverse events, vital signs, ECG and clinical laboratory parameters of BI 144807 in the same patient group.</brief_summary>
	<brief_title>A 4 Week Study With BI 144807 in Patients &gt;= 50 Years With Wet Age Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Inclusion criteria: Newly diagnosed men and women with unilateral subfoveal choroideal neovascularization secondary to agerelated macular degeneration Exclusion criteria: Additional eye disease that could compromizse best corrected visual acuity, such as uncontrolled glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>